Finance

Lists
Why is KARD up 11.98%?
Dive Deeper
KARD:NASDAQ
Kardigan Inc
$15.52
+11.98%
(+1.66) 1D
$15.70
+1.16% (+0.18)
After hours
Closed: Nov 6, 4:00:01 PM GMT-5  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for KARD...
Open
$14.00
High
$15.56
Low
$13.57
Mkt. cap
1.45B
Avg. vol.
587.71K
Volume
406.63K
52-wk high
$27.00
52-wk low
$12.23
EPS
-$6.54
No. of employees
241
Open
$14.00
High
$15.56
Low
$13.57
Mkt. cap
1.45B
Avg. vol.
587.71K
Volume
406.63K
52-wk high
$27.00
52-wk low
$12.23
EPS
-$6.54
No. of employees
241
News stories
From web sources and news partners
About Kardigan Inc
CEO-
Employees241
Founded2023
Headquarters-
SectorHealth Care
IndustryPharmaceutical industry
Websitekardigan.bio
Analyst ratings
Based on 6 analysts giving stock ratings to KARD in the past 3 months
Strong buy
Buy
6
Hold
0
Sell
0
12-month forecast
Based on 6 Wall Street analysts offering 12 month price targets for KARD in the last 3 months.
Highest
Current $15.52
$50.00 (+222.16%)
Average
$40.67 (+162.05%)
Lowest
$25.00 (+61.08%)
Analyst
Recommendation
Action
Price target
Projected
Date
Joseph Pantginis
H.C. Wainwright
Buy
Initiated
$42.00
+170.6%
11/04/2026
Kristen Kluska
Cantor Fitzgerald
Buy
Initiated
$50.00
+222.2%
10/29/2026
Jack Allen
Robert W. Baird
Buy
Initiated
$43.00
+177.1%
10/21/2026
Unknown Analyst
William Blair
Buy
Initiated
$38.00
+144.8%
10/15/2026
Sharon Zackfia
William Blair
Buy
Initiated
$38.00
+144.8%
10/15/2026
Unknown Analyst
UBS
Buy
Initiated
$25.00
+61.1%
10/11/2026
Alice Nettleton
UBS
Buy
Initiated
$25.00
+61.1%
10/11/2026
Anupam Rama
J.P. Morgan
Buy
Reiterated
$46.00
+196.4%
08/25/2026
Roanna Ruiz
Leerink Partners
Buy
Initiated
$37.00
+138.4%
07/13/2026
Ritu Baral
TD Cowen
Buy
Initiated
$46.00
+196.4%
07/13/2026
Dennis Ding
Jefferies
Buy
Initiated
$40.00
+157.7%
07/13/2026
Previous reportsAll values in USD
Loading Previous Earnings...
Revenue
Net income
All values in USD
Mar 2025
Jun 2025
Mar 2026
Jun 2026
Revenue
-
-
-
-
Cost of goods sold
-
-
-
-
Cost of revenue
-
-
-
-
Research and development expenses
18.77M
33.24M
45.07M
56.36M
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
6.50M
9.59M
13.64M
18.87M
Operating expense
25.28M
42.82M
58.71M
75.23M
Total operating expenses
25.28M
42.82M
58.71M
75.23M
Operating income
-25.28M
-42.82M
-58.71M
-75.23M
Other non operating income
-2.17M
-1.39M
-154.00K
-43.77M
EBT including unusual items
-22.19M
-57.44M
-56.07M
-116.24M
EBT excluding unusual items
-26.62M
-43.14M
-56.07M
-116.24M
Income tax expense
-4.17M
-
-
-
Effective tax rate
18.78%
-
-
-
Other operating expenses
-
-
-
-
Net income
-18.02M
-57.44M
-56.07M
-116.24M
Net profit margin
-
-
-
-
Earnings per share
-
-
-
-2.89
Interest and investment income
832.00K
1.07M
2.79M
2.76M
Interest expense
-
-
-
-
Net interest expenses
832.00K
1.07M
2.79M
2.76M
Depreciation and amortization charges
-
-
-
-
EBITDA
-24.88M
-41.70M
-58.22M
-74.20M
Gain or loss from assets sale
-
-
-
-
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
Upcoming events
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer
Google apps